1. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with early breast cancer in each year from 2013 to 2018.
If confirm, please release this data.
2. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018. If confirm, please release this data.
3. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018. If confirm, please release this data.
4. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer in each year from 2013 to 2018. If confirm, please release this data.
5. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the numbers of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018. If confirm, please release this data.
6. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018. If confirm, please release this data.

Download response Breast cancer. 181019